Drug shows promise for kidney cancer brain metastases in early trial
NCT ID NCT00814021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib (a drug that blocks tumor growth and blood flow)
What this could lead to
If it works, this could offer a new treatment option for kidney cancer that has spread to the brain, potentially shrinking tumors and controlling the disease.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply widely. The drug may not shrink brain tumors effectively or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Claudius Regaud
Toulouse, 31052, France